What are the Key Drifts in the Microfluidics in Oncology Market?

The market has been expanding due to the growing funding, collaborations, and investments to launch and enhance the use of various microfluidic platforms.

• In June 2025, a total of €6 million in seed-stage funding was secured by Scope Biosciences B.V. by combining a follow-on investment from SHIFT Invest and Oost NL and a previously awarded €2.5 million EIC Transition Grant, along with other investments. This investment will be used to support the development of a next-gen CRISPR-based portable and field-ready molecular diagnostics platform, delivering ultra-precise, single-nucleotide detection, which is named scopeDx®.
• In May 2025, to develop a pilot-scale data using the High Volume Cyva System, a collaboration between CellFE and Made Scientific, which is a cell therapy CDMO, was announced. To utilize both activated and resting T cell manufacturing, the collaboration aims to validate the non-viral microfluidics-based gene editing platform of CellFE.
• In February 2025, to accelerate groundbreaking work in high-throughput analysis technologies, a total of $25,000,000 was raised by Atrandi Biosciences. These investments reflect the confidence of the investor in their innovative approach to improve and simplify droplet microfluidics and high-throughput screening (HTS) workflows.
• In November 2024, a successful closing of $7M seed round was announced by Parallel Fluidics, which is the fastest microfluidic device manufacturer in the world. This funding will be used to design, manufacture, commercialize, and expand the hardware and software solutions of its new product, MV-2.

What is the Significant Challenge in the Microfluidics in Oncology Market?

High cost acts as the major limitation in the market, making the device more expensive. These devices often require advanced infrastructure, sophisticated instruments, and reagents, which adds to the cost, limiting their adoption rates by small or limited infrastructure facilities. Moreover, the technical, integration, and standardization complexities are other market challenges.

Regional Analysis

Why did North America Dominate the Microfluidics in Oncology Market in 2024?

platforms used in oncology development of precision medicines

U.S. Driven by Advanced Industries

The U.S. consists of advanced industries that are contributing to the growing innovation of microfluidic devices to deal with the growing cancer cases. At the same time, the growing R&D investments are encouraging their development. Additionally, growing healthcare applications as well as technological innovations are also contributing to the same.

Download the single region market report @

Increasing R&D Propels Canada

Growing oncology R&D in the institutes and industries of Canada is increasing the use of microfluidic devices. They are being used for detecting cancer cells, or to develop therapy, as well as to monitor their response. Additionally, the growing number of startups are also innovating new platforms, promoting the growth in the development of next-generation diagnostics.

For instance,

• In August 2025, the development, commercialization, and expansion of a flagship next-generation digital microfluidics (DMF) electroporation platform is being accelerated by DropGenie, which is a Canadian biotech startup.
  

What Made the Asia Pacific the Fastest Growing Region in the Microfluidics in Oncology Market in 2024?

Asia Pacific is expected to host the fastest growth in the market during the forecast period, due to growing cancer cases, which are increasing the demand for accurate diagnosis and targeted treatment options. The expanding healthcare sector is increasing the development, adoption, and innovations of microfluidic platforms, which are being supported by government investment, making them more affordable. At the same time, the growing demand for personalized medicines are also promoting the market growth.

Rising Cancer Incidences Drive India

The growing cancer burden and the expanding healthcare system are increasing the use and demand for microfluidics in India. The growing demand for early and accurate diagnostics, preventive care, and less invasive diagnostics are increasing their adoption rates, where the industries are developing new devices like organ-on-a-chip

Become a valued research partner with us -

Large Population Boosts China

Due to the large population, the incidence of cancer in China is increasing, which is driving demand for cancer diagnostics

For instance,

• In August 2025, the successful completion of the first-ever clinical trial of implanted microelectrode arrays to precisely locate deep-seated brain tumors was announced by a Chinese-led team, which will focus on the development of brain-computer interface (BCI) technology.
  

Recent Developments in the Microfluidics in Oncology Market

• In July 2025, a leukemia-on-a-chip, which is a miniature device developed by combining both the physical structure of bone marrow and a functioning human immune system, to enhance the immunotherapy development, was launched by researchers of NYU Tandon School of Engineering.
• In April 2025, the Beacon DiscoveryTM Optofluidic System was launched by Bruker Corporation, which provides an entry point into live single-cell functional analysis.
• In November 2024, a new microfluidic platform called Recoverable-Spheroid-on-a-Chip with Unrestricted External Shape (ReSCUE) was developed by the University of Toronto's Faculty of Applied Science & Engineering researchers, which allows unprecedented control and manipulation of tumor shapes.
  

Immediate Delivery Available | Buy This Premium Research @

The global oncology automation market

The global oncology drugs market

The oncology clinical trial market

The global oncology API market

The oncology biosimilars market

Tele-oncology is rapidly advancing

The U.S. oncology drugs market

The global oncology next-generation sequencing (NGS) market

The global immuno-oncology drugs market

Microfluidics in Oncology Market Key Players List

• Revitty
• Illumina, Inc.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific, Inc.
• Abbot
• Bio-Rad Laboratories, Inc.
• thinXXS Microtechnology GmbH
• Danaher
• Standard Biotools

Download the Competitive Landscape market report @

Segments Covered in The Report

By Region

North America

• U.S.
• Canada

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
  

Europe

• Germany
• UK
• France
• Italy
• Spain
• Sweden
• Denmark
• Norway

Latin America

• Brazil Mexico
• Argentina

Middle East and Africa (MEA)

• South Africa
• UAE
• Saudi Arabia
• Kuwait

Immediate Delivery Available | Buy This Premium Research @

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard:

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research

You can place an order or ask any questions, please feel free to contact us at ...

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web:

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest